MedTrace Logo

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

NCT00689845 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-07-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with one of five different combination chemotherapy regimens may kill more cancer cells.

PURPOSE: This clinical trial is studying giving rituximab together with combination chemotherapy to see how well it works in treating patients with primary mediastinal diffuse large B-cell lymphoma.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

Given IV

BIOLOGICAL

filgrastim

Given subcutaneously

BIOLOGICAL

rituximab

given IV

DRUG

cyclophosphamide

Given IV

DRUG

cytarabine

Given subcutaneously

DRUG

doxorubicin hydrochloride

Given IV

DRUG

etoposide phosphate

Given IV

DRUG

ifosfamide

Given IV

DRUG

methotrexate

Given IV

DRUG

prednisolone

Given orally

DRUG

prednisone

Given orally

DRUG

vincristine sulfate

Given IV

DRUG

vindesine

Given IV

Sponsors & Collaborators

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Peter Johnson, MD · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689845 on ClinicalTrials.gov